Verified employee & interview reviews

Serum Institute of India Reviews

Pune, Maharashtra

4.7/ 5

3 reviews

Serum Institute of India Pvt. Ltd. (SIIPL) is an Indian multinational biotechnology and biopharmaceutical company headquartered in Pune, Maharashtra, and stands as the world's largest vaccine manufacturer by the number of doses produced and sold globally. Founded in 1966 by Dr. Cyrus Poonawalla, the company was established with the core objective of manufacturing life-saving immuno-biologicals that were facing severe shortages in India and were historically imported at prohibitively high prices. By introducing affordable, high-quality alternatives, the company successfully made India self-sufficient in Tetanus Anti-toxin and Anti-snake Venom serum, subsequently expanding into childhood immunizations and specialized biologicals. Today, the Serum Institute of India functions as the flagship entity of the Poonawalla Group and is wholly owned by the Poonawalla family through their holding company, Poonawalla Investments and Industries Private Limited. The organization is currently led by Founder and Chairman Dr. Cyrus Poonawalla alongside Chief Executive Officer Adar Poonawalla. The core operations of the Serum Institute revolve around the research, development, and mass manufacturing of specialized vaccines across several major segments, including bacterial vaccines, viral vaccines, and recombinant products. Its extensive product portfolio comprises vital vaccines for Polio, Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps, and Rubella. Notably, the company achieved significant global prominence through strategic international partnerships, such as its collaboration with the British-Swedish pharmaceutical giant AstraZeneca and the University of Oxford to manufacture Covishield (AZD1222), as well as its partnership with the Gamaleya Research Institute to produce the Sputnik V vaccine. It is estimated that approximately 65% of children worldwide receive at least one vaccine manufactured by the Serum Institute. Geographically, the company maintains a highly diversified revenue profile, with international exports accounting for roughly 82% of its total operations, supplying critical medical products to over 170 countries. Major global organizations, including the United Nations Children's Fund (UNICEF) and the Pan American Health Organization (PAHO), serve as primary international buyers. To sustain this massive global supply chain, the company operates state-of-the-art, cGMP-compliant manufacturing infrastructure distributed across 60 acres in Hadapsar and 58 acres in Manjari in Pune. Additionally, the company executed its first major international expansion in June 2012 by acquiring Bilthoven Biologicals from the Netherlands Government, giving it access to specialized Injectable Polio Vaccine (IPV) technology and an additional 40-acre manufacturing plant. Financially, the private enterprise exhibits exceptional strength, generating billions in revenue with robust operating margins (PBILDT margins consistently above 40%), strong cash accruals, and an entirely comfortable, debt-free or low-gearing capital structure.